Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: The panel on clinical practices for treatment of HIV

Annals of Internal Medicine

Volumn 137, Issue 5 II, 2002, Pages 381-433

  Dybul, Mark ^a   Fauci, Anthony S ^a   Bartlett, John G ^a   Kaplan, Jonathan E ^a   Pau, Alice K ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMIODARONE; AMPRENAVIR; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; BEPRIDIL; CALCIUM CHANNEL BLOCKING AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; FLECAINIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROPAFENONE; PROTEINASE INHIBITOR; QUINIDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

BONE MARROW SUPPRESSION; CLINICAL PRACTICE; DECISION MAKING; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; HEALTH CARE ORGANIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROPATHY; PATIENT ATTITUDE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT;

EID: 0037015184     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-137-5_part_2-200209031-00001     Document Type: Review

References (253)

1. Report of the NIH Panel To Define Principles of Therapy of HIV Infection and Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
2. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America
3. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
4. Plasma viral load and CD4+lymphocytes as prognostic markers of HIV-1 infection
5. Decay characteristics of HIV-1-infected compartments during combination therapy
6. Predictors of optimal virological response to potent antiretroviral therapy
7. CD4+lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: A review
8. Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection
9. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
10. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
11. Pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy
12. Phenotypic resistance testing significantly improves response to therapy: A randomized trial (VIRA3001)
13. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
14. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
15. Transmission of antiretroviral-drug-resistant HIV-1 variants
16. HIV-1 drug resistance in newly infected individuals
17. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
18. A controlled trial of zidovudine in primary human immunodeficiency virus infection
19. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: Results of the ANRS 053 trial
20. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant
21. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076
22. Antiretroviral (ARV) resistance mutations among pregnant, HIV-infected women: Frequency and clinical correlates
23. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
24. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
25. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
26. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
27. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy
28. Long-term survival after initiation of antiretroviral therapy [Abstract 341]
29. + lymphocyte level is better than HIV-1 plasma viral load in determining when to initiate HAART [Abstract 519]
30. Prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy: Multicohort analysis of 12,040 patients
31. Early initiation of combination antiretroviral therapy: Does it affect long-term outcome
32. 3
33. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
34. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
35. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
36. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy
37. Sex differences in HIV-1 viral load and progression to AIDS
38. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters
39. Serum levels of virus burden in early-stage human immunodeficiency virus type 1 disease in women
40. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter
41. Sex differences in HIV-1 viral load and progression to AIDS. Swiss HIV Cohort Study
42. Sex differences in HIV-1 viral load and progression to AIDS. ICONA Study Group. Italian cohort of HIV-1 positive individuals
43. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men
44. Lack of sex difference in CD4 to HIV-1 RNA viral load ratio
45. Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia
46. Gender specific differences in quantitative HIV-1 RNA levels
47. Plasma HIV RNA viral load in women and men with advanced HIV disease
48. Do gender differences in CD4 cell counts matter?
49. A prospective study of HIV disease progression in female and male drug users
50. Do gender differences in viral load predict differences in HIV disease progression
51. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
52. Factors influencing survival in HIV infected patients treated with HAART
53. Viral drug resistance, adherence and pharmacokinetic indices in HIV-1 infected patients on successful and failing protease inhibitor (PI) based highly active antiretroviral therapy (HAART)
54. Adherence and viral load in HIV-infected drug users: Comparison of self-report and medication events monitors (MEMS)
55. Adherence in AIDS clinical trials: A framework for clinical research and clinical care
56. Factors affecting adherence to antiretroviral therapy
57. Protease inhibitors in the homeless
58. Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study
59. Management of the adverse effects of antiretroviral therapy and medication adherence
60. Forum for Collaborative HIV Research. What do we know about adherence levels in different populations?
61. Overview of patient compliance with medication dosing: A literature review
62. Compliance/adherence and care management in HIV disease
63. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance
64. Adherence, compliance, and HAART
65. Recognizing the phenomenon of readiness: Concept analysis and case study
66. Adherence to combination antiretroviral therapies in HIV patients of low health literacy
67. Self-reported antiretroviral adherence correlates with HIV viral load and declines over time
68. Adherence and antiretroviral therapy in injection drug users
69. Community collaborations between physicians and pharmacists improves adherence with HIV Consensus Panel Guidelines (Guidelines) and enhances the care of HIV infected individuals
70. Provider estimate (PE) and structured patient report of adherence compared with unannounced pill count
71. Forum for Collaborative HIV Research. TREAT-a clinical management tool with adolescents
72. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men
73. Patient adherence to highly active antiretroviral therapy for HIV-1 infection in a nation-wide cohort study in the Netherlands
74. Factors associated with discontinuation of highly active antiretroviral therapy (HAART) in a large cohort of HIV-infected women
75. Coverage, adherence, and sustainability of antiretroviral therapy among injection drug users in Vancouver, Canada
76. Adherence to antiretroviral therapy is associated with results of pills identification test
77. Strategies to optimize adherence to highly active antiretroviral treatment
78. Correlation between antiretroviral pill burden and durability of virologic response
79. Potential advantages of a compact triple nucleoside regimen: Efficacy and adherence with combivir/abacavir versus combivir/indinavir in an open-label randomised comparative study (CNAB3014)
80. Forum for Collaborative HIV Research. Directly observed therapy
81. Forum for Collaborative HIV Research
82. Impact of directly observed therapy on outcomes in HIV clinical trials
83. Modified directly observed therapy (MDOT) to enhance highly active therapy (HAART): 12 Month follow-up
84. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection
85. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
86. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
87. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
88. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
89. Changing patterns of mortality across Europe in patients infected with HIV-1
90. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
91. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality
92. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS
93. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
94. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load
95. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study
96. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
97. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
98. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy
99. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection
100. Changes in thymic function with age and during the treatment of HIV infection
101. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
102. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
103. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection
104. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
105. Indinavir concentrations and antiviral effect
106. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study
107. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
108. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial
109. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy
110. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
111. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy
112. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir
113. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
114. Addition of a second protease inhibitor eliminates amprenavir-efavirenz interactions and increased amprenavir concentrations
115. Multiple-dose pharmacokinetics and tolerability of indinavir (IDV) ritonavir (RTV) combinations in healthy volunteers
116. Effect of ritonavir on increases in saquinavir plasma concentration is independent of ritonavir dosage: Combined analysis of 120 subjects
117. Influence of low doses of ritonavir on the pharmacokinetics of nelfinavir 1250 mg BID
118. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
119. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviralnaive adults with HIV-1 infection: 48-Week results
120. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors
121. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy
122. Lactic acidosis complicating antiretroviral therapy: Frequency and correlates
123. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy
124. Hyperlactatemia and antiretroviral therapy in the Swiss HIV Cohort Study
125. Lactic acidosis (LA) in patients receiving nucleoside reverse transcriptase inhibitors (NRTIs)
126. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 Fatal cases
127. Riboflavine and severe lactic acidosis
128. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity
129. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
130. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy
131. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
132. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens
133. Differences in anion gap with different nucleoside RTI combinations
134. Editorial response: Hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors
135. Blood lactate: Biochemistry, laboratory methods, and clinical interpretation
136. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases
137. Lactic acidosis associated with stavudine administration: A report of five cases
138. Survival of a human immunodeficiency patient with nucleoside-induced lactic acidosis-role of haemodialysis treatment
139. Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis
140. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
141. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
142. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor
143. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
144. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients
145. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy
146. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine
147. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy
148. Metabolic complications of antiretroviral therapies
149. Severe diabetes associated with protease inhibitor therapy
150. New-onset diabetes mellitus associated with use of protease inhibitor
151. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
152. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
153. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study
154. Abstract 6
155. Abstracts 1 and 2
156. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy
157. Studies of body composition and fat distribution in HIV-infected and control subjects
158. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
159. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999
160. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
161. From lipodystrophy syndromes to diabetes mellitus
162. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome
163. Visceral abdominal-fat accumulation associated with use of indinavir
164. Protease inhibitors and nucleoside analogue reverse transcriptase inhibitors interact to cause subcutaneous fat wasting in patients with HIV infection
165. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
166. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
167. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
168. Clinical factors related to the severity of fat redistribution in the HIV outpatient study (HOPS)
169. Strategy of antiretroviral switch studies-a review
170. Metformin in the treatment of HIV lipodystropby syndrome: A randomized controlled trial
171. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome
172. The HIV wasting syndrome: A review
173. Cumulative risk for developing hyperlipidemia in HIV-infected patients treated with protease inhibitors
174. 48-Week safety and efficacy results from a phase II study of a once-daily HIV-1 protease inhibitor (PI)
175. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
176. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral theraphy: Recommendations of the Adult AIDS Cilinical Trial Group Cardiovascular Disease Focus Group
177. Randomized open label trial of dietary advice with or without Pravastatin for the management of protease inhibitor (PI)-associated hypercholesterolemia
178. Randomized double-blind study of Gemfibrozil (GF) for the treatment of protease inhibitor-associated hypertriglyceridaemia
179. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy
180. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA
181. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy 1-year prospective follow-up of a multicenter, randomized, controlled study
182. Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: A case series
183. Osteonecrosis in HIV: A case-control study
184. Avascular necrosis of the hip (Leggs-Calve-Perthes Disease [LCPD]) in HIV-infected children in long-term follow up: PACTG Study 219
185. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy
186. High prevalence of avascular necrosis (AVN) of the hip in HIV infection: Magnetic resonance imaging of 339 asymptomatic patients
187. Case-control study of avascular necrosis in HIV-infected patients
188. Bone mineral density in patients with human immunodeficiency virus infection
189. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: Indication of normalization of the bone-remodeling process during highly active antiretroviral therapy
190. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
191. Osteopenia in a randomized, multicenter study of protease inhibitor (PI) substitution in patients with the lipodystrophy syndrome and well-controlled HIV viremia
192. Reduced bone mineral density of HIV-positive men: Association with protease-inhibitor therapy and low serum testosterone
193. Serum and urine markers of bone mineral metabolism in HIV-infected patients taking protease inhibitor containing potent antiretroviral therapy
194. Osteoporosis: Diagnosis, prevention, and treatment of established disease
195. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
196. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy
197. Hypersensitivity syndrome associated with efavirenz therapy
198. Sex differences in nevirapine rash
199. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy
200. Failure of a Short-Term Prednisone Regimen to Prevent Nevirapine-Associated Rash: A Double-Blind Placebo-Controlled Trial: The GESIDA 09/99 Study
201. Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?
202. The tolerability of efavirenz after nevirapine-related adverse events
203. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
204. Immune control of HIV-1 after early treatment of acute infection
205. SSITT: A prospective trial of strategic treatment interruptions in 128 patients
206. Randomized controlled trial on intermittent versus continuous HAART
207. Primary HIV infection: Host responses and intervention strategies
208. Primary human immunodeficiency virus type 1 infection: Review of pathogenesis and early treatment intervention in humans and animal retrovirus infections
209. Symptomatic primary infection due to human immunodeficiency virus type 1: Review of 31 cases
210. Clinical and epidemiologic features of primary HIV infection
211. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection
212. Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection
213. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection
214. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy
215. Update: Provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV
216. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000 copies/ml
217. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine
218. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission
219. Antiretroviral therapy for pregnant women
220. Pregnancy outcomes following systemic prenatal acyclovir exposure-June 1, 1984-June 30, 1993
221. Liver disease in pregnancy and fetal fatty acid oxidation defects
222. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women
223. A systemic and cellular model for zidovudine plasma concentrations and intracellular phosphorylation in patients
224. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites
225. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: A randomized, double-blind placebo-controlled study
226. Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1
227. Zidovudine in persons with asymptomatic HIV infection and CD4+cell counts greater than 400 per cubic millimeter
228. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission-Thailand, 1996-1998
229. Understanding the timing of HIV transmission from mother to infant
230. Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions
231. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract
232. Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women
233. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood
234. Viral load and heterosexual transmission of human immunodeficiency vires type 1
235. Determinants of HIV-1 shedding in the genital tract of women
236. Maternal viral load and vertical transmission of HIV-1: An important factor but not the only one
237. Randomized trial of STD control for maternal-infant health - Rakai, Uganda
238. Bacterial vaginosis: Evidence for sexual transmission and association with HIV-1 infection
239. Adverse health events occurring during an N-9 gel pilot study: Malawi
240. Male circumcision as an effective HIV prevention strategy: Current evidence
241. HIV incidence associated with male circumcision in a population-based cohort, and HIV acquisition/transmission associated with circumcision and viral load in discordant couples: Rakai, Uganda
242. Male circumcision and HIV spread in sub-Saharan Africa
243. Estrogen protects against vaginal transmission of simian immunodeficiency virus
244. Selenium deficiency is associated with shedding of HIV-1 infected cells in the female genital tract
245. HIV prevalence and associated risks in young men who have sex with men
246. Confidence in HAART and recent unprotected anal sex among men who have sex with men (MSM)
247. Non-adherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women
248. Unsafe sex among persons in HIV care is associated with decreased adherence with antiretroviral therapy